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ABSTRACT 
BACKGROUND:  As a living heart valve substitute with growth potential and improved durability, 
tissue-engineered heart valves (TEHV) may prevent re-interventions that are currently often needed in 
children with congenital heart disease. We performed early Health Technology Assessment to assess 
the potential cost-effectiveness of TEHV in children requiring right ventricular outflow tract 
reconstruction (RVOTR). 
METHODS: A systematic review and meta-analysis was conducted of studies reporting clinical 
outcome after RVOTR with existing heart valve substitutes in children (mean age ≤12 and/or 
maximum age≤21 years) published between 1/1/2000-2/5/2018. Using a patient-level simulation 
model, costs and effects of RVOTR with TEHV compared to existing heart valve substitutes were 
assessed from a healthcare perspective applying a 10-year time horizon. Improvements in 
performance of TEHV, divided in durability, thrombogenicity, and infection resistance, were explored to 
estimate quality-adjusted life years (QALY) gain, cost reduction, headroom, and budget impact 
associated with TEHV.  
RESULTS: Five-year freedom from re-intervention after RVOTR with existing heart valve substitutes 
was 46.1% in patients ≤2 years old and 81.1% in patients >2 years old. Improvements in durability had 
the highest impact on QALYs and costs. In the ‘improved TEHV performance’ scenario (durability≥5 
years and -50% other valve-related events), QALY gain was 0.074 and cost reduction was €10,378 
per patient, translating to maximum additional costs of €11,856 per TEHV compared to existing heart 
valve substitutes. 
CONCLUSIONS:  This study showed that there is room for improvement in clinical outcomes in 
children requiring RVOTR. If TEHV result in improved clinical outcomes, they are expected to be cost-
effective compared to existing heart valve substitutes.  
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The pulmonary valve is the most commonly affected heart valve in congenital heart disease.(1) During 
2014-2017, 3,488 right ventricle outflow tract reconstructions (RVOTR) were performed in the US.(2) 
Most children who undergo RVOTR need multiple re-interventions later in life, because existing heart 
valve substitutes cannot accommodate patient growth.(3) In contrast, tissue-engineering provides a 
promising method to create living heart valves with growth potential that may last a lifetime.(4-7) In this 
approach, a valve-shaped scaffold is implanted in the patients’ heart that recruits cells from the 
bloodstream and surrounding tissues and gradually transforms into an autologous valve while the 
scaffold degrades.(7) Preclinical studies on the performance of tissue-engineered heart valves (TEHV) 
and clinical trials of tissue-engineered vascular grafts showed promising results, but results of the first-
in-man clinical trial of TEHV are not available yet.(5-8) It is difficult to define minimum performance 
requirements of TEHV, because reports on performance of existing pulmonary valve substitutes in 
children are predominantly based on small single-center studies. Furthermore, when TEHV are 
introduced in clinical practice, healthcare decision makers do not only need assurance that TEHV 
improve clinical outcomes, but also that they are cost-effective compared to existing options to ensure 
optimal allocation of the limited healthcare budget.(9) Generating information on cost-effectiveness in 
early development phases can help set research priorities that ensure that TEHV will meet needs of 
patients, professionals, and payers. In this early Health Technology Assessment (HTA) study, we 
performed a systematic review and meta-analysis of published outcomes of RVOTR with existing 
heart valve substitutes in children and we estimated the potential cost-effectiveness, headroom and 
budget impact of TEHV using a patient-level simulation model.  
PATIENTS AND METHODS 
Systematic review and meta-analysis 
Embase, MEDLINE, Cochrane Central, Google Scholar, and Web-Of-Science databases were 
systematically searched for studies reporting on outcomes after RVOTR with a heart valve substitute 
or valved conduit in children (mean age≤12 and/or maximum age≤21 years) published between 1-1-
2000 and 2-5-2018. Relevant data was extracted from included studies and pooled using the inverse 
variance method in a random-effects model. Pooled Kaplan-Meier time-to-event meta-analysis was 
conducted by extrapolating and pooling estimates of individual patient time-to-event data from 
published Kaplan-Meier curves. Detailed descriptions of these methods are provided in Supplement 1. 
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Patient-level simulation 
We used a patient-level simulation model to compare costs and effectiveness of TEHV with existing 
pulmonary valve substitutes. The patient-level simulation model was based on our previously 
published conceptual model (Figure 1).(10) The model simulation starts with creating a virtual patient 
population by random sampling (with replacement) 25,000 patients from a Dutch health insurance 
claims database comprising 338 children (mean±SD 4.5±5.8 years) who underwent RVOTR between 
2010-2013 (Supplemental Table S1).(11) The number of 25,000 sampled patients was required to get 
stable results. For each patient, mortality and events within thirty days after the intervention are 
determined. Subsequently, time to late events and death are calculated. The event with the lowest 
predicted time value is considered to occur after which the consequences for quality of life and costs 
are modelled. Then, time to late events and death are calculated again. The simulation stops when 
death has the lowest predicted time value of all events or when the patient dies directly after an event. 
This process is repeated for all patients (Supplemental Figure S1). By combining data of all simulated 
patients, the average difference in quality-adjusted life years (QALY) and costs between TEHV and 
existing heart valve substitutes is calculated. The model was implemented in R3.3.2 using RStudio 
1.0.136.  
Mortality and events 
The events included in the model are presented in Figure 1/Supplemental Table S2. Mortality was 
divided into early mortality (≤30 days after intervention), mortality directly related to valve-related 
events, background mortality, and excess mortality. Background mortality was obtained for the year 
2016 in the Dutch general population.(12) Excess mortality is ascribed to the potential excess risk of 
dying of patients who underwent heart valve interventions which can be explained by increased 
occurrence of sudden death, underreporting of valve-related events, and underlying associated 
cardiac pathology.(13) This excess mortality was expressed as hazard ratio relative to background 
mortality. 
 
Risks and rates of mortality and events after RVOTR, probabilities of re-intervention or death after 
events, and the hazard ratio of excess mortality were derived from our systematic review and meta-
analysis (see Results section; Supplemental Table S3). The pooled freedom from re-intervention curve 
was used to generate time to structural valve deterioration using a Weibull distribution and was 
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corrected for re-interventions due to endocarditis and valve thrombosis. We were unable to determine 
distributions for other events based on our meta-analysis, therefore we assumed a constant hazard 
rate by using exponential distributions. Different input parameters were included for patients aged 
below or above two years at time of surgery based on the respective subgroups in our meta-analysis. 
When patients underwent a re-intervention during the simulation at an age above 2 years, the 
corresponding input parameters were applied for the rest of the simulation. 
Costs 
Healthcare costs included intervention, treatment of events and other healthcare use costs 
(Supplemental Table S3). Most costs were dependent on patient and intervention characteristics using 
(multilevel) generalised linear models ((M)GLM)(Supplemental Table S4; supplemental material 
reviewers only).(11) We assumed most complications had a permanent influence on healthcare use 
(e.g. lifelong follow-up with cardiologist after pacemaker implantation), except for prosthetic valve 
related events and re-intervention to avoid double counting of follow-up costs for the initial heart valve 
implantation. Other healthcare costs were calculated with the MGLM regression formula within three 
years after the intervention (Supplemental Table S5). Beyond three years, these costs were adjusted 
to patient age using relative increases in total healthcare costs by age and sex of the general 
population.(14)  
Health-related quality of life  
Health-related quality of life was expressed in utilities. Utility of patients after RVOTR without events 
was 0.852 (Supplement 2).(15) The utility was corrected for events using utility multipliers for a specific 
time duration after the event based on literature or assumptions (Supplemental Table S3).  
Tissue-engineered heart valves 
Exact costs and performance of TEHV are unclear, because they are not used in clinical practice as 
yet. Therefore, we made the following assumptions on TEHV performance. We assumed that safety 
will be established before TEHV are introduced in clinical practice, for this reason we did not include 
higher risks of early mortality or valve-related events. The procedure to implant TEHV is expected to 
be comparable to surgically implanting existing heart valve substitutes. Hence, we assumed that early 
mortality and event risks, which are mainly procedure-related and not valve-related, are comparable 
for TEHV and existing heart valve substitutes. Further, we assumed that probabilities to die or undergo 
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re-intervention after events were comparable to existing heart valve substitutes. To assess long-term 
performance of TEHV, three aspects of their potential benefits were considered important: (1) 
Improved durability due to growth potential and lower rates of structural valve deterioration (SVD) and 
non-structural valve dysfunction resulting in longer time to re-intervention; (2) Reduced 
thrombogenicity resulting in lower rates of prosthetic valve thrombosis and reduced need for 
anticoagulation treatment. (3) Improved infection resistance resulting in lower rates of endocarditis 
and subsequent hospitalization and/or re-intervention.  
Analyses  
Cost-effectiveness analyses were performed from a healthcare perspective applying a 10-year time 
horizon with costs expressed in 2016 Euros and effects in QALYs. Future health benefits and costs 
were discounted with 1.5% and 4%, respectively, according to Dutch HTA guidelines.(16)  
Several scenario analyses were performed to estimate the impact of variations in TEHV 
performance on costs, effects, and cost-effectiveness assuming that the price of TEHV is equal to that 
of existing heart valve substitutes (allograft/Contegra≈€5.000; other bioprostheses≈€2.500). First, we 
performed scenario analyses where performance components were varied separately with varying 
rates compared to existing heart valve substitutes. In the durability scenarios, the minimum durability 
of TEHV was 2.5, 5, 7.5, or 10 years. In the thrombogenicity and infection resistance scenarios, the 
occurrence of events was 25%, 50%, 75% and 100% less than with existing heart valve substitutes. 
Further, three scenario analyses where performance components of TEHV were varied simultaneously 
were performed. In the first combined scenario, we assumed ‘perfect performance’ of TEHV in which 
the occurrence of prosthetic valve-related events was equal to the level in the general population 
(≈zero). In the second combined scenario, we assumed ‘improved performance’ of TEHV in which 
the durability of TEHV was assumed to be ≥5 years and the rates of other prosthetic-valve related 
events were reduced with 50% compared to existing heart valve substitutes. In the final combined 
scenario, we assumed ‘partial improved performance’ of TEHV in which occurrence of events 
related to thrombogenicity and infection resistance were reduced with 50%, but prosthetic valve 
dysfunction increased with 50% due to shorter durability than existing heart valve substitutes. In 
addition, subgroup analyses were performed for patients aged ≤2 and >2 years for the ‘improved 
performance’ scenario. For all scenarios, we calculated the differences in costs andeffects, and the 
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incrementalcost-effectiveness ratio (ICER; difference in costs divided by difference in effects) of 
RVOTR with TEHV compared to existing heart valve substitutes.  
To reflect the uncertainty in input parameters of the patient-level simulation model (second-
order uncertainty) and to describe what this means for uncertainty in outcomes, we performed 
probabilistic sensitivity analyses (PSA; Supplement 3). PSA was performed for the ‘improved 
performance’ scenario and was implemented as a double loop: an inner loop, in which 500 patients 
were sampled with replacement, and an outer loop in which 500 sets of input parameters of the model 
were randomly drawn (Supplement 4). For each set of input parameters, mean outcomes over all 
patients were recorded and the mean and credible interval (i.e. 2.5% and 97.5% percentile) over all 
500 mean values for each outcome were calculated. PSA results were plotted in a cost-effectiveness 
plane reflecting the uncertainty around cost-effectiveness estimates. 
To estimate the maximum price of TEHV to remain cost-effective compared to existing heart 
valve substitutes, the headroom was calculated. The headroom was calculated with the following 
formula: (difference in QALYs*cost-per-QALY threshold)+cost savings. The cost-per-QALY threshold 
was €20,000/QALY (Supplement 3).  
Budget impact reflects the difference in total population-level costs of RVOTR with existing 
heart valve substitutes compared to TEHV. Budget impact analysis was performed for the ‘improved 
performance’ scenario for the first 10 years after introduction of TEHV. Differences in population-level 
costs were calculated by multiplying the differential total costs per patient with the expected number of 
candidates for RVOTR with TEHV, assuming substitution rates of 25, 50, 75 or 100% of existing heart 
valve substitutes by TEHV. The expected number of annual RVOTR candidates was assumed to be 
85, based on the average number of patients who underwent RVOTR in the Netherlands in the years 
2010-2013.(11)  
RESULTS 
Systematic review and meta-analysis of clinical outcomes 
The systematic literature search identified 12,233 studies. After applying inclusion and exclusion 
criteria, 62 studies were included (Supplemental Figure S2, references in Supplementary Material) 
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encompassing 7,358 patients (age at surgery ≤2 years:n=1,270; >2 years:n=6,088) with a pooled 
mean follow-up of 6.1±3.5 years (Table 1).  
Pooled estimates of patient and procedural characteristics, mortality, valve-related events and 
re-intervention risks and rates after RVOTR are presented in Supplemental Table S5. Five-year 
survival was 86.5% and 85.7% and freedom from re-intervention was 46.1%, and 81.1%, in patients 
aged below and above 2 years, respectively (Figure 2). Mortality not directly related to valve-related 
events (i.e. background mortality and excess mortality) was 2.5 times higher after RVOTR in patients 
≤2 years and 10 times higher after RVOTR in patients >2 years than in the general population 
(Supplement 5). 
Supplemental Table S3 presents the clinical input parameters of the patient-level simulation 
model derived from the meta-analyses. Early events besides stroke, re-exploration for bleeding, early 
RVOT re-intervention, valve thrombosis and endocarditis were reported too inconsistently and stroke 
and bleeding did not occur in any of the included studies and were therefore excluded from the 
analysis. 
Early Health Technology Assessment 
Table 2 presents cost-effectiveness results of the scenario analyses. Of the three TEHV performance 
components, durability had the highest impact on cost-effectiveness. This is emphasized by results of 
the ‘partial improved scenario’ where the consequences of reductions in durability of TEHV for the 
cost-effectiveness could not be offset by reduced thrombogenicity and improved infection resistance of 
TEHV. The ‘perfect performance’ scenario provides insight in the maximum QALY gain and cost 
savings of TEHV compared to existing heart valve substitutes: 0.107 QALYs and almost €21,000. In 
the ‘improved performance’ scenario, the assumed durability of TEHV of at least five years resulted in 
a reduction of occurrence of prosthetic valve dysfunction of 40%. In this scenario, RVOTR with TEHV 
resulted in a QALY gain of 0.058 and costs reduction of €10,378. Subgroup analyses showed QALY 
gains and cost reductions were higher in patients ≤2 years than in patients >2 years old at RVOTR 
(Supplemental Table S6-7). 
PSA of the ‘improved performance’ scenario showed that the difference in costs and effects 
varied, but all data points suggested QALY gains at lower costs. Consequently, the probability that the 
cost-effectiveness of TEHV would fall under the maximum cost-per-QALY was 100% for all thresholds.  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
9 
 
Depending on improvements in clinical outcomes with TEHV, the price of TEHV can be higher 
while remaining cost-effective compared to existing heart valve substitutes. When applying a cost-per-
QALY threshold of €20.000, this headroom varied from €12 if TEHV would only result in a small 
reduction in thrombogenicity to €23,041 if there would be no prosthetic valve related events at all 
using TEHV.  
Figure 4/Supplemental Table S8 shows that national cost savings in the next 10 years range 
from €1.9 million when 25% of RVOTR was performed with TEHV to €7.5 million when all RVOTR 
were performed with TEHV instead of existing heart valve substitutes.  
Extensive internal validation was performed to check the model’s performance using the 
TECH-VER checklist.(17) Further, Kaplan-Meier curves of survival and time to re-intervention derived 
from our meta-analysis that were used as input were comparable to curves derived from the model 
(Supplemental Figures S3-4). 
COMMENT 
In this study, we presented a virtual approach to assess the potential of the use of TEHV in children 
requiring RVOTR. The results of our meta-analysis indicated that there is room for improvement in the 
outcomes of existing pulmonary heart valve substitutes in children. If TEHV are associated with 
improved clinical outcomes, they are expected to be cost-effective compared to existing pulmonary 
heart valve substitutes in children. These results can be useful for different stakeholders.(10) First, this 
study informs patients and clinicians about expected outcomes after RVOTR with existing heart valve 
substitutes and potential outcomes of TEHV and therefore can support current and future treatment 
decision-making. Furthermore, raising awareness among clinicians about TEHV as future treatment 
option may result in faster adoption in clinical practice.(18) Second, our systematic review and meta-
analysis of outcomes after RVOTR with existing heart valve substitutes informs biomedical developers 
about minimum performance requirements of TEHV. Furthermore, we showed that developers should 
especially aim at optimizing durability of TEHV, as this was associated with the highest QALY gains 
and cost savings. In children, the real durability issue with existing heart valve substitutes is the one of  
patients outgrowing their conduit. This is illustrated in this study by the low freedom from re-
intervention in children who received a pulmonary valve substitute under 2 years of age. Considering 
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the low occurrence rates of valve-related events in this patient group, this can only be explained by 
patients outgrowing their pulmonary valve substitute. Therefore, developers should focus on realizing 
the growth potential of TEHV.  Depending on improvements in clinical outcomes, the price of TEHV 
can be higher than that of existing heart valve substitutes while remaining cost-effective. Finally, this 
study informs healthcare payers about potential upcoming market introduction of TEHV and its 
associated consequences for the healthcare budget, which may result in more timely decisions about 
reimbursement.(18) Although the annual number of children undergoing RVOTR in the Netherlands is 
small (85/year), large cost savings may be realized in the first decade after adoption of TEHV, varying 
from €1.9 million when 25% of RVOTR are performed with TEHV to €7.5 million when all RVOTR are 
performed with TEHV.  
Inherent to any early Health Technology Assessment, we had to make assumptions regarding 
the costs and clinical performance of TEHV. Therefore, this study presents a theoretical exercise and 
the results are a prediction of the potential cost-effectiveness of TEHV. This also implies that, although 
this study was aimed at TEHV, our results can be applied to any new technology that will improve 
durability, reduce thrombogenicity, and/or decrease infection risk of existing pulmonary heart valve 
substitutes used for RVOTR in children. It is uncertain if and when TEHV will be introduced in clinical 
practice and whether the performance will indeed be improved compared to existing heart valve 
substitutes. Preclinical and first-in-man clinical trials of tissue engineered heart valves and vascular 
grafts showed promising results and recently  a small-scale first-in-man clinical trial of tissue-
engineered pulmonary valved conduits for children with complex congenital heart disease was 
initiated.(6, 8) However, there are still several unresolved challenges regarding in-situ tissue 
engineering of heart valves, including finding the optimal material for the scaffold(19), the induction 
of regeneration of functional tissue(5), and finding the optimal balance between scaffold degradation 
and the formation of new tissue.(5)  
This study has several limitations. First, relationships between occurrence rates of valve-
related events after RVOTR on the one hand and patient and intervention characteristics and history 
of previous valve-related events on the other hand remains poorly defined and could, thus, not be 
incorporated in detail into our model. Instead, we used age subgroup-specific clinical input parameters 
to account for differences in these groups. Secondly, utility of patients after RVOTR was not based on 
patient-reported EQ-5D questionnaires in children. However, it is unlikely that possible inaccuracies in 
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estimations of the start utility had a large impact on cost-effectiveness results because the start utility 
was equal for the intervention and comparator. Thirdly, we did not apply a lifetime horizon because of 
limited follow-up of clinical outcomes after RVOTR with children. Further extrapolation of clinical 
outcomes would lead to substantial uncertainty. However, it is expected that a longer time horizon 
would only reflect higher cost savings due to more prevented re-interventions in adulthood. Further, 
we could not perform external validation of the results because of unavailability of an external dataset 
on outcomes after RVOTR in children. Finally, this study was performed from a Dutch perspective and 
may therefore not be generalizable to countries with other health care systems. 
In conclusion, this early HTA showed that TEHV developers should mainly focus on realizing 
the growth potential of TEHV because preventing patients from outgrowing their conduit and reducing 
the subsequent need for re-interventions was associated with the largest QALY gains and cost 
savings compared to existing heart valve substitutes in children requiring RVOTR. When biomedical 
developers succeed in realizing the growth potential, TEHV have the potential to be cost-effective 
compared to existing heart valve substitutes, commercially viable, and result in substantial savings for 
the national healthcare budget. 
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TABLES 
Table 1. Pooled estimates of patient characteristics and outcomes after RVOTR. 
  
≤2 years >2 years 
  Meta-analysis 
Included 
studies(n) 
I2, %(χ2  
P-value) Meta-analysis 
Included 
studies(n) 
I2, %(χ2  
P-value) 
Study characteristics  
No. of studies 19   37 
No. of patients 1270 19   6088 37 
Mean follow-up, years±SD 8.0±3.8 22   5.7±3.5 41 
Patient and intervention characteristics  
Mean age, years±SD 0.5±0.3 22   7.3±8.2 41 
Male, n(%) 248(51.4) 10   2110(57.4) 28 
Mean weight, years±SD 5.4±1.7 20   22.5±15.1 23 
Etiology 
 
22   40 
Tetralogy of Fallot(TOF)  183(14.6)   2235(42.5) 
Trucus arteriosus communis(TAC)  836(66.5)   687(13.1) 
Transposition great arteries(TGA)  15(1.2)    245(4.7)   
TGA + ventricular septal defect(VSD) + pulmonary stenosis(PS)  11(0.9)    182(3.5)   
Double outlet right ventricle(DORV)  13(1.0)    159(3.0)   
PS  2(0.2)    97(1.8)   
Previous cardiac intervention 
 
  
TOF repair 4(7.7) 1   183(40.3) 4 
Prior valved RVOTR  76(23.8) 5   1122(33.3) 22 
Palliative shunt  37(24.3) 3   242(22.8) 10 
Pulmonary valvuloplasty  4(2.6) 3   50(5.6) 8 
Valve prosthesis 
 
19   37 
Allograft  836(61.2) 19   2707(42.1) 30 
Bioprosthesis  529(38.7) 21   2590(40.3) 34 
Polytetrafluoroethylene(PTFE) - 16   1098(17.1) 27 
Early mortality and events,% 
            
Mortality 10.98(8.19-14.70) 20 55(0.002) 4.74(3.42-6.56) 29 74(0.000) 
RVOT reintervention 1.51(0.54-4.28) 4 0(0.768) 1.19(0.48-2.98) 7 26(0.227) 
Re-exploration for bleeding 6.22(1.10-35.11) 3 81(0.005) 3.54(1.70-7.37) 7 70(0.003) 
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Stroke 
- 0 - 1.69(0.76-0.00) 3 0(0.563) 
Valve thrombosis 
- 0 - 3.87(0.77-19.36) 4 78(0.003) 
Endocarditis 1.80(0.45-7.09) 2 0(0.878) - 1 - 
Late events,%/year 
            
Structural valve deterioration 
- 1 - 2.66(1.06-6.69) 3 76(0.014) 
Non-structural valve dysfunction 
- 0 - 0.60(0.23-1.57) 2 33(0.221) 
Endocarditis 
- 1 - 0.37(0.20-0.68) 12 58(0.006) 
Thromboembolism 
- 0 - 0.14(0.05-0.41) 7 45(0.092) 
Valve thrombosis 
- 0 - 0.11(0.02-0.78) 2 0(0.333) 
Bleeding 
- 0 - - 1 - 
Stroke 
- 0 - - 1 - 
Re-intervention 
            
RVOT re-intervention,%/year 8.05(5.44-11.90) 18 93(0.000) 4.65(3.67-5.88) 28 92(0.000) 
 - Surgical,% 72.4 13   68.8 15 
 - Percutaneous,% 27.6 13   31.2 15 
Conduit valve replacement,% of total reinterventions   
 - Surgical 94.2 16   94.9 22 
 - Percutaneous 2.6 7   26.7 9 
Late mortality, %/year 
            
Total mortality 1.39(0.99-1.95) 19 44(0.023) 0.75(0.58-0.97) 33 59(0.000) 
Cardiac mortality 0.49(0.27-0.86) 12 0(0.876) 0.38(0.27-0.53) 23 11(0.311) 
Valve-related mortality 0.59(0.28-1.28) 11 0(0.920) 0.28(0.17-0.47) 23 27(0.115) 
Sudden unexplained death 0.45(0.19-1.07) 10 0(0.992) 0.14(0.08-0.24) 22 0(0.783) 
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Table 2. Cost-effectiveness results of scenario analyses. 
  
LY QALYs Costs ∆LYs ∆QALYs ∆Costs ICER Headroom 
Existing pulmonary valve substitutes 9.086 6.959 99,944 
 
    
Separate improvements in TEHV performance components* 
Durability 
 
       
No prosthetic valve dysfunction events 9.170 7.065 79,377 0.083 0.106 -20,568 TEHV dominates 22,688 
Durability of TEHV≥7.5 years (-67% events) 9.163 7.055 85,017 0.076 0.096 -14,927 TEHV dominates 16,847 
Durability of TEHV≥5 years (-40% events) 9.144 7.032 89,741 0.058 0.073 -10,203 TEHV dominates 11,673 
Durability of TEHV≥2.5 years (-19% events) 9.117 6.994 94,254 0.031 0.036 -5,691 TEHV dominates 6,405 
Thrombogenicity 
 
       
No VT events 9.086 6.959 99,901 0.000 0.000 -43 TEHV dominates 47 
75% less VT events 9.086 6.959 99,911 0.000 0.000 -33 TEHV dominates 37 
50% less VT events 9.086 6.959 99,922 0.000 0.000 -23 TEHV dominates 27 
25% less VT events 9.086 6.959 99,934 0.000 0.000 -10 TEHV dominates 12 
Infection resistance 
 
       
No endocarditis events 9.087 6.960 99,539 0.001 0.001 -406 TEHV dominates 428 
75% less endocarditis events 9.087 6.959 99,655 0.001 0.001 -289 TEHV dominates 303 
50% less endocarditis events 9.087 6.959 99,762 0.000 0.000 -183 TEHV dominates 193 
25% less endocarditis events 9.087 6.959 99,832 0.000 0.000 -113 TEHV dominates 123 
Combined improvements in TEHV performance components* 
Perfect performance (no prosthetic valve related events) 9.171 7.066 79,042 0.084 0.107 -20,903 TEHV dominates 23,041 
Improved performance (durability ≥5 years and 50% less 
other prosthetic valve related events) 9.144 7.033 89,567 0.058 0.074 -10,378 TEHV dominates 11,856 
Partial improved performance (decreased durability with 50%, 
50% less other prosthetic valve related events) 8.976 6.931 123,741 -0.111 -0.028 23,796 
Existing heart valve 
substitutes dominate -24,356 
*Results of subgroup analyses can be found in table S6-7. 
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FIGURE LEGENDS 
Figure 1. Conceptual model 
Figure 2. Pooled Kaplan-Meier survival and freedom from re-intervention (both surgical and percutaneous re-
intervention) curves. Survival curve of general population was based on weighted survival tables from Europe, United 
States, and Asia for the pooled median year of intervention among included studies (2001) at the same mean age and 
proportion of males imported in the microsimulation model with valve-related mortality and events set to zero. (20, 21) 
Figure 3. Probabilistic sensitivity analyses of RVOTR with TEHV (‘improved performance’ scenario) compared to 
existing heart valve substitutes. Incremental: difference between RVOTR with TEHV and existing heart valve 
substitute. QALY: quality-adjusted life year. 
Figure 4. Cumulative cost savings in the first 10 years after introduction of RVOTR with TEHV (‘improved 
performance’ scenario) compared to existing heart valve substitutes. 
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